Skip to content

Transcranial magnetic stimulation (TMS) in the treatment of refractory bipolar depression: a preliminary study

Transcranial magnetic stimulation (TMS) in the treatment of refractory bipolar depression: a preliminary study - Transcranial magnetic stimulation (TMS) in the treatment of refractory bipolar depression

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000022148
Enrollment
40
Registered
2016-05-09
Start date
2016-05-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar depression

Interventions

Low-frequency right prefrontal transcranial magnetic stimulation for 4 weeks

Sponsors

National Center Hospital, National Center of Neurology and Psychiatry
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. DSM-5 diagnosis of bipolar disorder, major depressive disorder 2. HAMD 17 score >= 18 3. Current episode duration < 3 y 4. Patient does not respond to the medications described below for more than 8 weeks. i. Lithium, 0.8mmol/L ii. Quetiapine, 300mg/day iii. Olanzapine, 5-20mg/day iv. Lamotrigine, 200mg/day

Exclusion criteria

Exclusion criteria: 1. Rapid cycler type 2. Patient has a history of psychotic episode, OCD, PTSD, and eating disorder. 3. Patient had a previous treatment with ECT, TMS, VNS, DBS, and tDCS within 6 months. 4. Patient did not respond to ECT and TMS previously. 5. Pregnancy 6. Patient has a history of epilepsy and convulsion. Personal or close family history of seizure disorder 7. Neurologic disorder, organic brain disease 8. Substance or alcohol dependence 9. Ferromagnetic material in body or close to head 10. Severe metabolic disease, endocrine disease 11. Active suicide idea 12. Taking medications known to lower seizure threshold

Design outcomes

Primary

MeasureTime frame
Changes in the total score of Hamilton's Rating Scale for Depression (HAMD 17 items) at week 4

Countries

Japan

Contacts

Public ContactShinsuke Kito

National Center of Neurology and Psychiatry Department of Psychiatry and Advanced Medical Technology

kito@ncnp.go.jp042-341-2711

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026